Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F19%3A10400345" target="_blank" >RIV/00216208:11140/19:10400345 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00216224:14310/19:00113450 RIV/00669806:_____/19:10400345

  • Výsledek na webu

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=osgd-_ZUQo" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=osgd-_ZUQo</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s00066-019-01491-0" target="_blank" >10.1007/s00066-019-01491-0</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences

  • Popis výsledku v původním jazyce

    Purpose This article reports experiences with 3T magnetic resonance imaging(MRI)-guided brachytherapy (BT) for cervical cancer focusing on late side effects. Methods Between June 2012 and March 2017 a total of 257 uterovaginal BT administrations were performed in 61 consecutive patients with inoperable cervical cancer. All patients were treated with BT combined with external beam radiotherapy. Results The mean HR-CTV (high risk-clinical target volume) D-90 was 87 &amp; x202f;+/- 5.1 &amp; x202f;Gy equivalent dose corresponding to the conventional fractionation using 2 &amp; x202f;Gy per fraction (EQD2, range 70.7-97.9 &amp; x202f;Gy). The mean doses in OAR (organs at risk), namely rectum, sigmoid and bladder were D2 &amp; x202f;cm(rectum)(3)&amp; x202f;= 62.6 &amp; x202f;+/- 6.9 &amp; x202f;Gy EQD2 (range 38.2-77.2 &amp; x202f;Gy), D2 &amp; x202f;cm(sigmoid)(3)&amp; x202f;= 66.2 &amp; x202f;+/- 6.8 &amp; x202f;Gy EQD2 (43.2-78.6 &amp; x202f;Gy) and D2 &amp; x202f;cm(bladder)(3)&amp; x202f;= 75.1 &amp; x202f;+/- 8.3 &amp; x202f;Gy EQD2 (58.2-92.6 &amp; x202f;Gy). There were no signs of late gastrointestinal (GI) toxicity in 49 patients, grade 3 toxicity was seen in 2 patients and grade 4 toxicity in 3 patients. There were no signs of late genitourinary (GU) toxicity in 41 patients, grade 3 toxicity was seen in 4 patients and no signs of grade 4 toxicity were seen. After the treatment, 60 patients (98.4%) achieved locoregional remission. In 54 patients (88.5%) the remission was complete, whereas in 6 patients (9.8%) remission was partial. Conclusion The use of 3T MRI-guided BT leads to achievement of high rates of local control with limited late morbidity as demonstrated in this series of patients.

  • Název v anglickém jazyce

    Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences

  • Popis výsledku anglicky

    Purpose This article reports experiences with 3T magnetic resonance imaging(MRI)-guided brachytherapy (BT) for cervical cancer focusing on late side effects. Methods Between June 2012 and March 2017 a total of 257 uterovaginal BT administrations were performed in 61 consecutive patients with inoperable cervical cancer. All patients were treated with BT combined with external beam radiotherapy. Results The mean HR-CTV (high risk-clinical target volume) D-90 was 87 &amp; x202f;+/- 5.1 &amp; x202f;Gy equivalent dose corresponding to the conventional fractionation using 2 &amp; x202f;Gy per fraction (EQD2, range 70.7-97.9 &amp; x202f;Gy). The mean doses in OAR (organs at risk), namely rectum, sigmoid and bladder were D2 &amp; x202f;cm(rectum)(3)&amp; x202f;= 62.6 &amp; x202f;+/- 6.9 &amp; x202f;Gy EQD2 (range 38.2-77.2 &amp; x202f;Gy), D2 &amp; x202f;cm(sigmoid)(3)&amp; x202f;= 66.2 &amp; x202f;+/- 6.8 &amp; x202f;Gy EQD2 (43.2-78.6 &amp; x202f;Gy) and D2 &amp; x202f;cm(bladder)(3)&amp; x202f;= 75.1 &amp; x202f;+/- 8.3 &amp; x202f;Gy EQD2 (58.2-92.6 &amp; x202f;Gy). There were no signs of late gastrointestinal (GI) toxicity in 49 patients, grade 3 toxicity was seen in 2 patients and grade 4 toxicity in 3 patients. There were no signs of late genitourinary (GU) toxicity in 41 patients, grade 3 toxicity was seen in 4 patients and no signs of grade 4 toxicity were seen. After the treatment, 60 patients (98.4%) achieved locoregional remission. In 54 patients (88.5%) the remission was complete, whereas in 6 patients (9.8%) remission was partial. Conclusion The use of 3T MRI-guided BT leads to achievement of high rates of local control with limited late morbidity as demonstrated in this series of patients.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30204 - Oncology

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2019

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Strahlentherapie und Onkologie

  • ISSN

    0179-7158

  • e-ISSN

  • Svazek periodika

    195

  • Číslo periodika v rámci svazku

    11

  • Stát vydavatele periodika

    DE - Spolková republika Německo

  • Počet stran výsledku

    10

  • Strana od-do

    972-981

  • Kód UT WoS článku

    000494072900003

  • EID výsledku v databázi Scopus

    2-s2.0-85069001370